BFRI
NASDAQ
US
Biofrontera Inc. - Common Stock
$0,98
▲ +$0,06
(+6,41%)
Vol 132K
4
Skor Kualitas
fail
Pendapatan ✗
Laba Bersih ✗
>IPO ✗
Kap. Pasar
$6.6M
ROE
-216,0%
Margin
-47,3%
D/E
899,15
Beta
0,53
52W
$1–$2
Konsensus Wall Street
8 analis · Apr 20262
Beli Kuat
5
Beli
1
Tahan
0
Jual
0
Jual Kuat
87,5%
Peringkat Beli
Grafik Harga
Saham Serupa
LPCN
Lipocine Inc
$44.6M
HIND
Vyome Holdings Inc
$19.4M
CURX
Curanex Pharmaceuticals Inc
$9.4M
TRAW
Traws Pharma Inc
$9.0M
JUNS
Jupiter Neurosciences Inc
$35.1M
CVKD
Cadrenal Therapeutics Inc
$15.9M
CALC
CalciMedica Inc
$95.0M
RVPH
Reviva Pharmaceuticals Holdings Inc
$32.1M
HOTH
Hoth Therapeutics Inc
$15.4M
SNES
Senestech Inc
$11.1M
Pendapatan
Tingkat beat: 20,0%
Laporan Berikutnya
Mei 13, 2026
Estimasi EPS: $-0,12
| Kuartal | EPS Estimasi | EPS Aktual | Kejutan |
|---|---|---|---|
| Mar 2026 | $-0,12 | — | — |
| Des 2025 | $0,20 | $0,48 | +$0,28 |
| Sep 2025 | $-0,59 | $-0,62 | $-0,03 |
| Jun 2025 | $-0,43 | $-0,57 | $-0,14 |
Pendapatan & Laba Kuartalan
| Kuartal | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Pendapatan | $9.0M | $12.6M | $8.6M | $9.0M | $7.0M |
| Laba Bersih | -$5.7M | -$1.4M | -$4.2M | -$5.3M | -$6.6M |
Tren Fundamental
| Metrik | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -216.0% | -216.0% | -216.0% | -216.0% | -216.0% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -59.0% | -30.3% | -42.3% | -42.3% | -42.3% | -47.3% |
| Gross Margin | 70.7% | 53.3% | 59.0% | 59.0% | 59.0% | 64.4% |
| D/E Ratio | — | 899.15 | 899.15 | 899.15 | 899.15 | 899.15 |
| Current Ratio | 0.96 | 1.40 | 0.96 | 0.96 | 0.96 | 1.15 |
Rasio Utama
ROA (TTM)
-94,7%
P/S (TTM)
0,18
P/B
1,9
EPS (TTM)
$-1,84
CF/Share
$-19,36
Pertumbuhan Pendapatan 3T
+15,7%
52W High
$1,87
52W Low
$0,54
$0,54
Rentang 52 Minggu
$1,87
Kesehatan Keuangan
Arus Kas Bebas
-$3.8M
Utang Bersih
$1.5M
Kas
$3.4M
Total Utang
$4.9M
Per tanggal Sep 30, 2025
Як BFRI виглядає на тлі конкурентів у Pharmaceuticals?
Група порівняння: Micro-cap Pharmaceuticals (All) · 171 компаній
Оцінка BFRI vs аналоги Pharmaceuticals
P/E
—
▼
0%
di bawah
rekan
(22,4)
vs Rekan
vs Industri
Undervalued
P/S
0,2
▼
96%
di bawah
rekan
(5,0)
vs Rekan
vs Industri
Undervalued
P/B
1,9
▼
10%
di bawah
rekan
(2,1)
vs Rekan
vs Industri
Nilai wajar
Дивідендна дохідність
—
▼
0%
di bawah
rekan
(2,0%)
vs Rekan
vs Industri
Yield rendah
Прибутковість BFRI vs аналоги Pharmaceuticals
ROE
-216,0%
▼
298%
di bawah
rekan
(-54,3%)
vs Rekan
vs Industri
Lemah
Net margin
-47,3%
▲
0%
di atas
rekan
(-47,4%)
vs Rekan
vs Industri
Lemah
Валова маржа
64,4%
▼
6%
di bawah
rekan
(68,3%)
vs Rekan
vs Industri
Lemah
ROA
-94,7%
▼
153%
di bawah
rekan
(-37,4%)
vs Rekan
vs Industri
Lemah
Фінансове здоровʼя BFRI vs аналоги Pharmaceuticals
D/E ratio
899,2
▲
58286%
di atas
rekan
(1,5)
vs Rekan
vs Industri
Utang tinggi
Поточна ліквідність
1,2
▼
66%
di bawah
rekan
(3,4)
vs Rekan
vs Industri
Likuiditas rendah
Beta
0,5
▼
43%
di bawah
rekan
(0,9)
vs Rekan
vs Industri
Lebih volatil
Радар фундаменталів BFRI
BFRI
Median rekan
Industri
BFRI прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
BFRI vs аналоги: ключові метрики
Aktivitas Orang Dalam
NeutralPembelian
0
Penjualan
0
LUEBBERT HERMANN
Chief Executive Officer · Mar 05
137500 shs
LEFFLER EUGENE FREDERICK
Chief Financial Officer · Mar 05
87500 shs
Terakhir 90 hari
Pemegang Terbesar
Top 5: 19,47%Rosalind Advisors, Inc.
9,79%
$934K
AIGH Capital Management LLC
7,86%
$750K
Vanguard Group Inc
0,98%
$93K
Geode Capital Management, L…
0,56%
$54K
Jane Street Group, LLC
0,28%
$27K
Per tanggal Des 31, 2025
Berita Terbaru
Belum ada berita terkait